Cytos bullish on prospective vaccine deal

Swiss researchers claim to have found a 'one size fits all' allergy shot for hay fever, asthma and eczema, adding that it could be available within four to five years, the Telegraph reports. The vaccine is formed of synthetic DNA similar to those found in the bug that causes tuberculosis, Marie Claire reports. And Cytos is looking to clinch a partnering deal worth more than 600 million Swiss francs ($541 million) for the vaccine, Reuters reports. CEO Wolfgang Renner said in an interview with Swiss weekly Handelszeitung the group was starting talks to sell the license for the drug. Story

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.